CN1882557A - 4－氧代－4,5－二氢－呋喃－2－羧酸衍生物及其治疗代谢相关病症的方法 - Google Patents

4－氧代－4,5－二氢－呋喃－2－羧酸衍生物及其治疗代谢相关病症的方法 Download PDF

Info

Publication number
CN1882557A
CN1882557A CNA2004800340741A CN200480034074A CN1882557A CN 1882557 A CN1882557 A CN 1882557A CN A2004800340741 A CNA2004800340741 A CN A2004800340741A CN 200480034074 A CN200480034074 A CN 200480034074A CN 1882557 A CN1882557 A CN 1882557A
Authority
CN
China
Prior art keywords
methyl
phenyl
furan
dihydro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800340741A
Other languages
English (en)
Chinese (zh)
Inventor
金杰俈
格雷默·森普尔
本杰明·R·约翰逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN1882557A publication Critical patent/CN1882557A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800340741A 2003-11-21 2004-11-18 4－氧代－4,5－二氢－呋喃－2－羧酸衍生物及其治疗代谢相关病症的方法 Pending CN1882557A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52426903P 2003-11-21 2003-11-21
US60/524,269 2003-11-21

Publications (1)

Publication Number Publication Date
CN1882557A true CN1882557A (zh) 2006-12-20

Family

ID=34632884

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800340741A Pending CN1882557A (zh) 2003-11-21 2004-11-18 4－氧代－4,5－二氢－呋喃－2－羧酸衍生物及其治疗代谢相关病症的方法

Country Status (10)

Country Link
US (2) US20070093545A1 (enExample)
EP (1) EP1701947B1 (enExample)
JP (1) JP2007512346A (enExample)
CN (1) CN1882557A (enExample)
AT (1) ATE440828T1 (enExample)
AU (1) AU2004293415A1 (enExample)
CA (1) CA2545823A1 (enExample)
DE (1) DE602004022864D1 (enExample)
ES (1) ES2331521T3 (enExample)
WO (1) WO2005051937A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
KR100826108B1 (ko) 2006-08-04 2008-04-29 한국화학연구원 퓨란-2-카복실산 유도체 및 그의 제조 방법
US20110082202A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Fatty acid acifran derivatives and their uses
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN109416406B (zh) * 2016-07-05 2023-06-20 深圳帧观德芯科技有限公司 具有不同热膨胀系数的接合材料

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169202A (en) * 1978-06-05 1979-09-25 American Home Products Corporation Process for preparing 4,5-dihydro-4-oxofuran-2-carboxylic acid derivatives
US4244958A (en) * 1979-05-10 1981-01-13 American Home Products Corporation Hypolipidemic derivatives of 4,5-dihydro-4-oxofuran-2-carboxylic acid
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
DE60327446D1 (de) 2002-10-10 2009-06-10 Arena Pharm Inc 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie
US20060122240A1 (en) 2002-11-05 2006-06-08 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
WO2005011677A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
CN101076331A (zh) 2004-11-05 2007-11-21 艾尼纳制药公司 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
AU2006214286A1 (en) 2005-02-18 2006-08-24 Arena Pharmaceuticals, Inc. Methods and compositions for the treatment of lipid-associated disorders
WO2006127595A1 (en) 2005-05-23 2006-11-30 Arena Pharmaceuticals, Inc. 5-aminopyrazole carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
EP1924709A1 (en) 2005-08-10 2008-05-28 Arena Pharmaceuticals, Inc. Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist

Also Published As

Publication number Publication date
DE602004022864D1 (de) 2009-10-08
EP1701947B1 (en) 2009-08-26
WO2005051937A2 (en) 2005-06-09
WO2005051937A8 (en) 2006-08-31
ES2331521T3 (es) 2010-01-07
US20070161701A1 (en) 2007-07-12
WO2005051937A3 (en) 2005-09-15
CA2545823A1 (en) 2005-06-09
JP2007512346A (ja) 2007-05-17
AU2004293415A1 (en) 2005-06-09
EP1701947A2 (en) 2006-09-20
US20070093545A1 (en) 2007-04-26
ATE440828T1 (de) 2009-09-15
US7803837B2 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
CN1054850C (zh) 用于治疗的哌嗪化合物
CN1114596C (zh) 联苯基衍生物
US7241792B2 (en) Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
CN1993124A (zh) 取代吡唑、含有这种化合物的组合物及其应用
CN1204327A (zh) 药用活性喹唑啉类化合物
CN1788008A (zh) 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
CN1177844C (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1067244A (zh) 吡咯烷酮
CN1950334A (zh) 邻位取代的芳基或杂芳基酰胺化合物
CN1561212A (zh) 作为毒蕈碱试剂的苯并咪唑啉酮衍生物
CN1118781A (zh) 具有抗糖尿病活性的杂环化合物及其制备和用途
CN1604776A (zh) 作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物
CN1867562A (zh) 四唑衍生物和其代谢相关的疾病的治疗方法
CN1169792C (zh) 取代的乙烯基吡啶衍生物和含有它们的药物
CN1726189A (zh) 新颖的mch受体拮抗剂
CN1040748C (zh) 苯并吖庚因衍生物及其药物组合物和中间体
CN1681777A (zh) 作为maob抑制剂的吡咯烷酮衍生物
CN1625554A (zh) 氨基烷基－取代的氮杂环丁烷、吡咯烷、哌啶与氮杂环庚烷的酰胺
CN1043319A (zh) 新的胺类及其用途
CN1918160A (zh) 用作趋化因子受体活性调节剂的新颖三环螺环衍生物
CN1838956A (zh) 作为雄激素受体调节剂化合物的6－环氨基－2－喹啉酮衍生物
CN1993321A (zh) 作为单胺再摄取抑制剂的3－氨基－1－芳基丙基吲哚类化合物
CN1745069A (zh) 用作ccr2受体拮抗剂的巯基咪唑
CN1735595A (zh) 取代的烷基酰氨基哌啶
CN1930146A (zh) 哌啶基羰基－吡咯烷和它们作为黑皮质素激动剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication